US Material Events SEC 8-K Filings — July 15, 2026

15-07-2026

Senti Biosciences Holdings, Inc. (SNTI) announced a strategic transaction to spin off its gene-circuit-enabled pipeline, including SENTI-202, into a new privately held company (NewCo) controlled by affiliates of its largest investor, Celadon. In exchange, SBH will receive a contingent value right (CVR) providing up to $60 million in milestone payments over seven years tied to SENTI-202's success. Post-closing, SBH will focus on its Regulator Dial™ platform for controllable gene therapies, including a Rett Syndrome program and armored TILs for solid tumors, while seeking additional financing. The transaction has been approved by SBH's board and is subject to stockholder approval and other customary conditions.

• · SENTI-202 has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation.
• · Phase 1 trial for SENTI-202 showed durable MRD-negative responses in 22 patients with relapsed/refractory AML.
• · Donor X characteristic is found in ~50% of adult donors and is independent of HLA or KIR matching.
• · NewCo will also advance other Logic Gate-enabled therapies for solid tumors and Gene-Circuit-powered programs such as in vivo CAR.
• · SBH plans to seek additional financing after closing to focus on early-stage programs.
• · The transaction is subject to stockholder approval and other customary closing conditions.

15-07-2026

Hycroft Mining Holding Corporation announced the appointment of Michael Deal as Senior Vice President and Chief Operating Officer, effective August 24, 2026. Mr. Deal brings over 20 years of operating and technical leadership experience in North American gold and silver operations, including roles at First Majestic Silver, Nevada Gold Mines, and Newmont Corporation. The company highlighted his expertise in sulfide processing and refractory ore treatment as directly relevant to advancing the Hycroft Mine, particularly the high-grade silver systems Brimstone and Vortex.

• · Michael Deal is a Registered Member and Qualified Person (QP) with the Society for Mining, Metallurgy & Exploration (SME).
• · He holds a Bachelor of Science in Chemical Engineering with a minor in Economics from the Colorado School of Mines and an MBA from Arizona State University.
• · Mr. Deal serves on the SME Foundation Board of Directors and has previously served on the Nevada Mining Association Board of Directors and the Nevada Mineral Processing Division Board.
• · The company is advancing to the next phase of operations for processing sulfide mineralization at the Hycroft Mine.

15-07-2026

AEON Biopharma announced the pricing of an upsized $13.75 million underwritten public offering with milestone warrants that could provide up to an additional $29.6 million in gross proceeds if fully exercised in cash, for total potential gross proceeds of approximately $43.3 million. The offering includes 42,688,606 shares of common stock (or pre-funded warrants) accompanied by two-year and five-year milestone warrants tied to regulatory and clinical development milestones for ABP-450, a proposed biosimilar to BOTOX®. Proceeds will be used for working capital and general corporate purposes, including comparative analytical testing on ABP-450 to support biosimilarity.

• · The offering is expected to close on or about July 15, 2026.
• · Lake Street Capital Markets, LLC is acting as sole bookrunner; Laidlaw & Company (UK) Ltd. is lead manager.
• · Registration Statement on Form S-1 (File No. 333-297327) was declared effective on July 13, 2026.
• · The two-year milestone warrants expire on the earlier of the second anniversary or 45 days after public announcement of a specified regulatory milestone for ABP-450.
• · The five-year milestone warrants expire on the earlier of the fifth anniversary or 45 days after public announcement of a specified clinical development milestone for ABP-450.
• · The representative has a 30-day option to purchase up to an additional 6,403,290 shares and/or warrants to cover over-allotments.
• · ABP-450 is manufactured by Daewoong Pharmaceutical in a facility authorized by the FDA, Health Canada, and EMA for third-party botulinum toxin products.

15-07-2026

Sunbelt Rentals Holdings, Inc. completed the issuance of $450M in 4.950% Senior Notes due 2030 and $750M in 5.650% Senior Notes due 2036 on July 14, 2026. The notes were issued at discounts of 99.627% and 99.048%, respectively, and are guaranteed by the company's domestic subsidiaries. The proceeds will be used for general corporate purposes, and the notes rank equally with existing senior debt.

• · The notes were issued in a private placement exempt from SEC registration under Rule 144A and Regulation S.
• · Interest on both notes is payable semi-annually on February 12 and August 12, beginning February 12, 2027.
• · The company may redeem the 2030 Notes at any time prior to July 12, 2030 at specified redemption prices, and at par thereafter.
• · The company may redeem the 2036 Notes at any time prior to May 12, 2036 at specified redemption prices, and at par thereafter.
• · Upon a change-in-control triggering event, the company must offer to repurchase the notes at 101% of principal plus accrued interest.
• · The indenture includes covenants limiting sale/leaseback transactions, liens on assets, and mergers/asset sales, with customary exceptions.
• · Events of default include nonpayment, covenant breaches, payment defaults on other indebtedness, and bankruptcy/insolvency.

15-07-2026

Gossamer Bio, Inc. filed an 8-K on July 15, 2026, reporting that at a special meeting of stockholders held on July 14, 2026, shareholders approved an amendment to the company's Amended and Restated Certificate of Incorporation. The amendment increases the authorized capital stock from an unspecified prior amount to 4,070,000,000 shares, consisting of 4,000,000,000 shares of Common Stock and 70,000,000 shares of Preferred Stock. The filing also covers items related to director/officer changes (Items 5.02, 5.03, 5.07, 9.01), but the exhibit only details the charter amendment; no specific officer departures or elections are described in the provided content.

• · The amendment was approved at a special meeting of stockholders held on July 14, 2026.
• · The certificate of amendment was executed on July 14, 2026, and filed with the Delaware Secretary of State.
• · The company was originally known as FSG Bio, Inc. and filed its original Certificate of Incorporation on October 26, 2015.
• · The par value per share for both Common and Preferred Stock is $0.0001.

15-07-2026

T. Rowe Price Active Crypto ETF (TKNZ) disclosed the entry into two material agreements to facilitate spot crypto trading. The Sponsor entered a Digital Asset Trading Agreement with StoneX Digital LLC and a Liquidity Provider Agreement with Virtu Financial Singapore Pte. Ltd., both dated June 12, 2026 and May 15, 2026 respectively. The filings detail standard liability limitations and indemnification provisions but contain no financial figures, performance metrics, or period-over-period comparisons.

• · The Fund's eligible crypto assets include BTC, ETH, SOL, XRP, ADA, AVAX, LTC, DOT, DOGE, HBAR, BCH, LINK, XLM, SHIB, SUI, HYPE, and BNB.
• · The Digital Asset Trading Agreement with StoneX was dated June 12, 2026; the Liquidity Provider Agreement with Virtu Financial Singapore was dated May 15, 2026.
• · Both agreements allow spot purchase/sale transactions on a principal-to-principal basis and continue until terminated in writing by either party.
• · Under the StoneX agreement, StoneX has no liability for third-party acts/omissions, system failures, or consequential damages except those caused by its gross negligence or willful misconduct.
• · Under the Virtu agreement, VFS has no liability for third-party acts/omissions or system failures not maintained by VFS.
• · Each agreement contains mutual indemnification provisions covering breaches, legal violations, and reliance on instructions, which survive termination.
• · The Fund is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.

15-07-2026

Cytek Biosciences disclosed the departure of Chief Legal Officer and Corporate Secretary Valerie Barnett, effective June 29, 2026, and entered into a severance agreement and a consulting agreement for transition support. The severance includes a lump sum payment of $365,775.12 and COBRA premium coverage, with enhanced change-in-control benefits if a transaction occurs within three months. The consulting agreement provides for up to 10 hours per week at $1,000 per hour through August 31, 2026, with continued equity vesting.

• · Valerie Barnett's position terminated on June 29, 2026; severance agreement signed July 9, 2026.
• · COBRA premiums covered through earlier of April 30, 2027 or new employer coverage.
• · In a change-in-control within 3 months, Barnett would receive 18 months base salary plus 2026 bonus target, with prior severance credited.
• · Change-in-control also triggers COBRA premium coverage through January 31, 2028 and full acceleration of outstanding equity awards.
• · Consulting agreement effective July 10, 2026, initial term through August 31, 2026, with possible extension.
• · During consulting term, previously granted equity awards under 2021 Equity Incentive Plan continue to vest.

15-07-2026

Tennessee Valley Authority (TVC) entered into a Third Amended and Restated July Maturity Credit Agreement dated July 10, 2026, establishing a $1.00 billion credit facility with Toronto Dominion (Texas) LLC as Administrative Agent and The Toronto-Dominion Bank, New York Branch as a lender and L/C issuer. The agreement amends and restates the prior Second Amended and Restated March Maturity Credit Agreement from March 25, 2022, and re-evidences any outstanding credit extensions. The facility is intended for general corporate purposes and is issued under Section 15d of the TVA Act.

• · The agreement is dated July 10, 2026 and filed as an 8-K on July 15, 2026.
• · The facility replaces the Second Amended and Restated March Maturity Credit Agreement dated March 25, 2022.
• · The lead arranger and bookrunner is TD Securities (USA) LLC.
• · The facility includes provisions for letters of credit, expansion options, and extension of the termination date.

15-07-2026

Vaxcyte, Inc. announced the retirement of board member Heath Lukatch effective July 16, 2026, and the appointment of John Markels as a Class II director and member of the Audit and Compensation Committees, effective the same day. Dr. Lukatch's departure was not due to any disagreement with the company. The annual equity grant for directors is currently set at $430,000.

• · Dr. Lukatch served on the Board for over eight years.
• · Dr. Markels was appointed upon recommendation of the Nominating and Corporate Governance Committee.
• · Dr. Markels qualifies as an independent director under Nasdaq Rule 5605(a)(2).
• · No arrangements or understandings exist between Dr. Markels and any other person regarding his selection as a director.
• · No reportable transactions under Item 404(a) of Regulation S-K exist between the company and Dr. Markels.
• · Dr. Markels will receive compensation per the company's non-employee director compensation program, with the annual equity grant value currently set at $430,000.
• · The company entered into its standard form of indemnification agreement with Dr. Markels.

15-07-2026

Regen BioPharma Inc. settled a lawsuit with Trillium Partners, LP by agreeing to issue shares of Common Stock or Series A Preferred Stock to satisfy $398,740 in claims, with the court approving the issuance under Section 3(a)(10) of the Securities Act on July 10, 2026. The company also changed its independent auditor from BCRG Group to Simon & Edward LLP after BCRG's attest business was acquired, and authorized a new Series N Preferred Stock with super-voting rights (75 million votes per share). The company continues to face a going concern qualification from its former auditor and previously disclosed material weaknesses in internal controls.

• · The settlement shares are to be issued in one or more tranches, subject to adjustment and ownership limitations.
• · The Remittance Amount is defined as 65% of Net Proceeds from the sale of Settlement Shares.
• · BCRG's audit reports for FY2024 and FY2025 contained a going concern explanatory paragraph.
• · There were no disagreements or reportable events between the company and BCRG, except for previously disclosed material weaknesses in internal control over financial reporting.
• · The Series N Preferred Stock has 75,000,000 votes per share and votes together with common stock as a single class on all matters.

15-07-2026

Prestige Consumer Healthcare Inc., through its subsidiary Prestige Brands Inc., issued $400.0 million of 6.250% senior notes due 2034 in a private offering. The notes are senior unsecured obligations guaranteed by the parent company and certain subsidiaries, with interest payable semi-annually starting January 15, 2027, and maturing July 15, 2034. The company has the option to redeem the notes at specified prices on or after July 15, 2029, or earlier with a make-whole premium, and up to 40% may be redeemed with equity offering proceeds before that date.

• · Interest payment dates: January 15 and July 15 each year, beginning January 15, 2027.
• · Maturity date: July 15, 2034.
• · Notes are senior unsecured obligations of Prestige Brands and guaranteed on an unsecured senior basis by the parent company and certain domestic restricted subsidiaries.
• · The indenture contains covenants restricting the company's ability to incur additional debt, pay dividends, redeem stock, incur liens, sell assets, merge, or transact with affiliates, subject to exceptions.
• · The offering was conducted as a private placement exempt from SEC registration under Rule 144A and Regulation S.
• · No prior period financial data is presented in this filing for comparison.

15-07-2026

On July 10, 2026, Ensysce Biosciences, Inc. received a resignation notice from Jeffrey Millard, its Chief Operating Officer, effective immediately. The departure is a senior management change, but no financial details or replacement plans were disclosed in the filing.

• · The resignation was effective immediately on July 10, 2026.
• · No reason for departure or successor was mentioned in the filing.
• · The filing was made under Item 5.02 (Departure of Directors or Certain Officers) and Item 9.01 (Financial Statements and Exhibits).

15-07-2026

TriCo Bancshares (TCBK) has entered into a definitive agreement to be acquired by First Hawaiian, Inc. (FHB) in a stock-for-stock merger valued at an exchange ratio of 2.095 shares of First Hawaiian common stock for each share of TriCo common stock. The transaction, structured as a tax-free reorganization, includes a first-step merger of a First Hawaiian subsidiary into TriCo, followed by a second-step merger of TriCo into First Hawaiian and a subsequent bank-level merger of Tri Counties Bank into First Hawaiian Bank. The deal is subject to regulatory approvals, shareholder approvals, and other customary closing conditions.

• · The merger is structured as a single integrated transaction intended to qualify as a reorganization under Section 368(a) of the Internal Revenue Code.
• · Concurrently with the agreement, each member of TriCo's Board of Directors entered into a voting agreement to support the transaction.
• · The closing is expected to occur on the first business day of the month following satisfaction of all conditions, with a potential earlier close if conditions are met within the first ten calendar days of a month.
• · The agreement includes customary termination provisions, including a termination fee (amount not specified in the filing excerpt).

15-07-2026

Celsius Holdings entered into a Second Refinancing Amendment to refinance its existing $694.75M term loans with new 2026 Term Loans of the same amount, extending the maturity date and amending credit terms. The refinancing includes a cashless conversion option for existing lenders and is expected to close upon satisfaction of customary conditions.

• · The refinancing involves a cashless conversion option for existing term loan lenders.
• · The amendment modifies the U.S. Security Agreement and the Credit Agreement dated April 1, 2025.
• · Conditions include delivery of legal opinions, solvency certificate, and KYC documentation.

15-07-2026

Aspira Women's Health Inc. entered into a subordinated business loan and security agreement with Agile Capital Funding, LLC and Agile Lending, LLC on July 1, 2026, securing a term loan. The loan proceeds will be used to pay off a prior balance of $447,300 and for general business requirements. The agreement includes a $50,000 administrative agent fee, a prepayment fee equal to all remaining interest through maturity, and a default interest rate increase of 5 percentage points.

• · The loan is subordinated and secured by substantially all assets of the borrower.
• · The loan may only be prepaid with a make-whole premium equal to all remaining interest through maturity.
• · Default interest rate is the contract rate plus 5.00% per annum.
• · Interest is computed on a 360-day year basis.
• · The borrower represents that there is no litigation involving more than $500,000 pending or threatened.
• · The borrower represents solvency and no material adverse change since the most recent financial statements.

15-07-2026

Mobia Medical, Inc. appointed Dr. Reza Zadno as a new independent Class III director on July 14, 2026, expanding the board from six to seven members. Dr. Zadno brings extensive experience as former CEO of PROCEPT BioRobotics and Avedro, and will serve on the Compensation Committee. No financial figures or period-over-period comparisons are included in this filing.

• · Dr. Zadno's term as Class III director expires at the 2029 annual meeting.
• · Dr. Zadno served as President and CEO of PROCEPT BioRobotics from February 2020 to September 2025.
• · Dr. Zadno served as President and CEO of Avedro from September 2016 to November 2020.
• · Dr. Zadno has been an Operating Partner at Jolt Capital since February 2026.
• · Dr. Zadno is a Special Advisor to the American Academy of Ophthalmology since January 2024.
• · No transactions between Dr. Zadno and Mobia requiring Item 404(a) disclosure.

15-07-2026

RLI Corp. appointed James H. Bradshaw, Chairman of Gallagher Re North America, to its Board of Directors effective July 15, 2026. Bradshaw brings over 40 years of insurance industry leadership experience. His term expires at the next shareholders' meeting in May 2027, when he will stand for re-election.

• · Bradshaw served as CEO of Gallagher Re North America and its predecessor Willis Re North America for over a decade before becoming Chairman in 2024.
• · Prior to Willis Re, Bradshaw held leadership and underwriting roles at Guy Carpenter and Chubb.
• · RLI's insurance subsidiaries are all rated A++ 'Superior' by AM Best Company.

15-07-2026

The Hartford announced the appointment of Randy Larsen to its Board of Directors, effective September 1, 2026. Larsen, former CEO of AssuredPartners, brings deep insurance industry expertise and will serve on the Finance, Investment and Risk Management Committee and the Nominating and Corporate Governance Committee. The filing contains no financial results or period-over-period comparisons.

• · Larsen served as CEO of AssuredPartners from 2023 through its acquisition by Gallagher in 2025.
• · He will serve on the Finance, Investment and Risk Management Committee and the Nominating and Corporate Governance Committee.
• · Larsen earned a bachelor’s degree in finance from Nebraska Wesleyan University.

15-07-2026

RxSight, Inc. announced a planned leadership transition effective July 20, 2026, appointing Aziz Mottiwala as President and CEO, while founder Ron Kurtz, MD steps down as CEO to become Chief Medical Officer. Dr. Kurtz will also resign from the Board of Directors, with Mr. Mottiwala joining the Board. The company stated it is not updating its previously communicated financial guidance in connection with this announcement.

• · Mr. Mottiwala most recently served as Chief Commercial Officer at Tarsus Pharmaceuticals and previously held the same role at Opiant Pharmaceuticals.
• · Before that, he spent more than a decade at Allergan in senior leadership positions across the eye care franchise.
• · Mr. Mottiwala holds a B.S. in Biochemistry from UC San Diego and an MBA from USC.
• · Dr. Kurtz will resign from the Board of Directors, and Mr. Mottiwala will be appointed to the Board.
• · The company is not updating its previously communicated financial guidance.

15-07-2026

RetinalGenix Technologies Inc. disclosed that its independent auditor, Liebman Hymowitz, LLP, resigned effective July 13, 2026, and the company has engaged Vilki & Co. as its new auditor for the year ending December 31, 2026. The resignation was not due to any disagreements or reportable events, but the prior audit reports included an explanatory paragraph about substantial doubt regarding the company's ability to continue as a going concern. This change introduces uncertainty about financial oversight continuity, though no adverse accounting issues were cited.

• · The prior audit reports for years ended December 31, 2025 and 2024 included an explanatory paragraph about substantial doubt regarding the company's ability to continue as a going concern.
• · No disagreements or reportable events occurred during the years ended December 31, 2025 and 2024, and the subsequent interim period through July 13, 2026.
• · The company had not consulted with Vilki & Co. on any accounting, auditing, or financial reporting matters prior to engagement.

15-07-2026

First Hawaiian, Inc. (Parent) has entered into a definitive agreement to acquire TriCo Bancshares (Company) in a stock-for-stock merger valued at an exchange ratio of 2.095 shares of Parent Common Stock per share of Company Common Stock. The transaction is structured as a two-step merger followed by a bank merger, intended to qualify as a tax-free reorganization. The deal is subject to regulatory approvals and shareholder votes from both companies.

• · The merger consideration is 2.095 shares of Parent Common Stock per share of Company Common Stock.
• · The transaction is intended to qualify as a reorganization under Section 368(a) of the Internal Revenue Code.
• · Concurrently with the agreement, each member of the Company's Board of Directors entered into a voting agreement to support the merger.
• · The closing is expected to occur on the first business day of the month following satisfaction of all conditions, with specific timing adjustments based on the Last Condition Satisfaction Date.

15-07-2026

Socket Mobile, Inc. appointed former director Brent MacDonald to its Board of Directors, effective July 13, 2026. MacDonald previously served on the board from 2016 to 2023, and his return expands the board to six members, four of whom are independent. The filing contains no financial results or period-over-period comparisons, so no quantitative performance data is available.

• · Brent MacDonald previously served on Socket Mobile's Board from 2016 to 2023.
• · The appointment was effective July 13, 2026, and announced via press release on July 15, 2026.
• · The board now consists of six members, with four independent directors under Nasdaq listing standards.

15-07-2026

The Dayton Power and Light Company (AES Ohio) appointed Robert Osborn as Controller and principal accounting officer effective July 10, 2026. Sherry Kohan will continue as Vice President and CFO. Mr. Osborn, 44, previously served as Director of Revenue Accounting, Internal Controls and Finance Transformation of AES US Utilities since March 2025 and holds similar officer roles at other AES affiliates. No financial results or period-over-period comparisons are included in this filing.

• · Mr. Osborn previously served as Director of Revenue Accounting, Internal Controls and Finance Transformation of AES US Utilities since March 2025 and Director of Internal Controls and Finance Transformation from August 2024 to February 2025.
• · He also serves as Controller and principal accounting officer of DPL, IPALCO and AES Indiana since July 2026.
• · Prior to rejoining AES in June 2024, Mr. Osborn was Corporate Controller of USIC from July 2023 to June 2024.
• · He initially joined AES in August 2013 and held roles including Assistant Controller of AES US Utilities from March 2021 to July 2023.
• · Mr. Osborn holds a B.S. from Towson University, a Graduate Certificate in Advanced Accounting from University of Maryland Global Campus, an M.B.A. from University of Baltimore, and an M.S. in Finance from Indiana University.
• · AES Ohio does not separately compensate individuals for service as officers or directors; Mr. Osborn participates in AES management compensation plans generally exceeding $120,000 annually.

15-07-2026

IPALCO Enterprises, Inc. appointed Robert Osborn as Controller and principal accounting officer of IPALCO and its subsidiary AES Indiana, effective July 10, 2026. Sherry Kohan will continue as Vice President and CFO, relinquishing the Controller role. Mr. Osborn brings extensive experience from prior roles within AES and other companies, and his compensation exceeds $120,000 annually through AES affiliate plans.

• · Robert Osborn, age 44, previously served as Director of Revenue Accounting, Internal Controls and Finance Transformation of AES US Utilities since March 2025.
• · Mr. Osborn also serves as Controller and principal accounting officer of DPL and AES Ohio since July 2026.
• · He initially joined AES in August 2013 and held various roles including Assistant Controller of AES US Utilities from March 2021 to July 2023.
• · Mr. Osborn holds a B.S. from Towson University, a Graduate Certificate in Advanced Accounting from University of Maryland Global Campus, an M.B.A. from University of Baltimore, and an M.S. in Finance from Indiana University.
• · IPALCO and AES Indiana do not separately compensate officers or board members for their service; compensation is provided through AES affiliate plans.

15-07-2026

American Airlines Group Inc. elected John W. Dietrich, former EVP and CFO of FedEx Corporation, to its board of directors, effective July 15, 2026. Dietrich will serve on the Audit and Finance Committees, bringing 35 years of aviation and air cargo experience. The appointment is a routine board refreshment with no financial impact or negative metrics reported.

• · Dietrich most recently served as EVP and CFO of FedEx Corporation from 2023 to 2026.
• · He previously served as President and CEO of Atlas Air Worldwide and spent over a decade at United Airlines as an attorney.
• · Dietrich currently chairs the National Defense Transportation Association and serves on the boards of AAR Corporation and First Horizon Corporation.
• · American Airlines operates more than 6,000 daily flights to over 350 destinations in more than 60 countries.
• · The airline serves more than 200 million customers annually and employs 130,000 people.
• · American Airlines celebrates its centennial year in 2026.

15-07-2026

Runway Growth Finance Corp. entered into an Eighth Amendment to its Credit Agreement, waiving two defaults: a late closure of a Wells Fargo brokerage account and the unauthorized acquisition of MOD3 Pharma Inc. (which has since been merged into the borrower). Simultaneously, four lenders (Mitsubishi HC Capital America, Zion Bancorporation, Hancock Whitney Bank, and Valley National Bank) were repaid in full and exited the facility, and DZ Bank's commitment was reduced from $65M to $30M, with a further potential termination by December 31, 2026. The amendment also includes a 0.10% amendment fee to remaining lenders and a release of claims by the borrower against the administrative agent and lenders.

• · The amendment waives two specific defaults: (1) failure to close a Wells Fargo brokerage account by April 30, 2026 (Account Closure Default), and (2) unauthorized acquisition of MOD3 Pharma Inc. without lender consent and failure to have MOD3 guarantee the obligations (MOD Event of Default).
• · MOD3 Pharma Inc. has been merged into the borrower as of the amendment date.
• · The amendment fee to remaining lenders is 0.10% of each lender's commitment.
• · DZ Bank's commitment was reduced from $65M to $30M, and the borrower may further terminate DZ Bank's remaining commitment by December 31, 2026, subject to no continuing default.
• · The borrower released all claims against the administrative agent, lenders, and related parties arising from the transaction documents.

15-07-2026

Infinity Natural Resources appointed Timothy Dugan to its Board of Directors on July 13, 2026. Dugan brings over 40 years of leadership experience in the Appalachian energy industry, including roles as CEO of Olympus Energy and COO of CNX Resources. The appointment strengthens the Board's operational and strategic expertise as the company executes its long-term growth strategy.

• · Dugan most recently led Olympus Energy through its sale to EQT Corporation.
• · He previously served as EVP and COO of CNX Resources and as a director of CNX Midstream Partners LP.
• · Earlier career includes senior roles at Chesapeake Energy, Equitable Production Company, and Cabot Oil & Gas Corporation.
• · Dugan holds a B.S. in Chemical Engineering from the University of Pittsburgh.

15-07-2026

Fermi Inc. announced the closing of an upsized $431.25 million convertible notes offering (5.00% due 2031) to strengthen liquidity and support Project Matador, its advanced energy and AI campus in Texas. The company highlighted a shareholder-friendly capped call structure that limits dilution until the stock price doubles, and net proceeds of approximately $416.81 million will be used for general corporate purposes and to fund the capped call transactions. However, the offering adds $431.25 million in debt to the balance sheet, and the company has not yet signed binding tenant agreements, with project ramp-up dependent on those agreements.

• · The notes mature on July 15, 2031, with a five-year term.
• · Initial conversion price is approximately $9.52 per share (30% premium).
• · Effective conversion price after capped call is $14.64 per share (100% premium).
• · Project Matador is expected to integrate combined-cycle natural gas, nuclear, solar, battery storage, and utility grid power.
• · Fermi has not yet signed binding tenant agreements; ramp depends on those agreements.

15-07-2026

Palmer Square Capital BDC Inc. completed a $300.00 million CLO reset transaction on July 15, 2026, refinancing its term debt securitization through Palmer Square BDC CLO 1, Ltd. The transaction issued $228.00 million of AAA Class A-R Notes (Term SOFR + 1.28%) and $72.00 million of AA Class B-R Notes (Term SOFR + 1.75%), both due 2039. The company retains 100% of the subordinated notes and has irrevocably waived all collateral management fees payable to it.

• · The CLO reset transaction is backed by a diversified portfolio of senior secured loans, with potential for second lien loans, corporate bonds, and DIP financing.
• · The notes mature on July 15, 2039, and may be redeemed by the Issuer at the written direction of a majority of the Subordinated Notes or the Company on any business day on or after the Refinancing Date.
• · The Secured Notes are secured obligations of the Issuer; the Subordinated Notes are unsecured.
• · The Notes have not been and will not be registered under the Securities Act of 1933 or state securities laws.
• · The company has irrevocably waived all collateral management fees payable to it under the Collateral Management Agreement.

15-07-2026

Samos Energy Acquisition Corporation announced the pricing of its initial public offering of 20,000,000 units at $10.00 per unit, with units trading on the NYSE under the ticker "SAMO.U" starting July 10, 2026. The SPAC intends to focus on acquiring operational, cash-generative international energy assets. The offering includes a 45-day underwriter option for up to an additional 3,000,000 units.

• · Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant exercisable at $11.50 per share.
• · The registration statement was declared effective by the SEC on July 9, 2026.
• · The SPAC is sponsored by Samos Energy Acquisition Sponsor, LP, which is affiliated with Samos Investments LLC, a special situations investor in traditional energy assets.

15-07-2026

Autonomix Medical, Inc. (NASDAQ: AMIX) entered into a warrant inducement agreement with an investor to immediately exercise outstanding November 2025 Warrants for 428,731 shares at a reduced exercise price of $6.00, generating approximately $2.6 million in gross proceeds. In consideration, the company will issue unregistered Series D-1 and D-2 warrants to purchase an aggregate of 857,462 shares at $5.75 per share, expiring in five and a half years. The transaction is expected to close on or about July 15, 2026, subject to customary conditions.

• · The November 2025 Warrants were originally issued on November 19, 2025.
• · The resale of shares from the November 2025 Warrants is registered under Form S-3 (File No. 333-291825).
• · Maxim Group LLC acted as warrant inducement agent and financial advisor.
• · The New Warrants are being offered in a private placement exempt from registration under the Securities Act of 1933.
• · The company's technology is investigational and not yet cleared for marketing in the U.S.

15-07-2026

Q32 Bio Inc. entered into an underwriting agreement on July 14, 2026 to sell 6,027,399 shares of common stock at $18.25 per share and 4,931,506 pre-funded warrants at $18.2499 per warrant, raising estimated net proceeds of $187.6 million (or $215.8 million if the underwriters' option is fully exercised). The offering is expected to close on July 16, 2026, and proceeds will be used for working capital, including research, clinical development, and commercialization of bempikibart. The filing does not disclose any prior-period financial data, so no period-over-period comparisons are available.

• · The offering was made under a shelf registration statement on Form S-3 (File No. 333-297027) filed June 25, 2026 and declared effective July 13, 2026.
• · Pre-funded warrants are exercisable at any time after issuance and expire when exercised in full, with an ownership limit of 4.99% or 9.99% (adjustable up to 19.99% on 61 days' notice).
• · The company does not intend to list the pre-funded warrants on any national securities exchange.
• · Underwriters have a 30-day option to purchase up to an additional 1,643,835 shares of common stock.

15-07-2026

The Hanover Insurance Group announced CEO succession: John C. Roche will retire as President and CEO on December 31, 2026, and COO Richard W. Lavey has been named CEO-elect to ensure a smooth transition. The company highlighted strong financial position and record operating earnings under Roche's leadership, but no specific financial metrics for the current period were provided in the filing.

• · Roche, 62, joined The Hanover in 2006 and became CEO in 2017.
• · Lavey, 59, joined The Hanover in 2004 and currently serves as COO and president of Hanover Agency Markets.
• · Lavey previously held roles including chief marketing officer, chief growth innovation officer, president of personal lines, and president of northeast region.
• · Lavey is a Phi Beta Kappa graduate of The College of Holy Cross and holds an MBA from Harvard Business School.
• · The company will answer questions at its earnings call on July 29, 2026, and will share strategy update at investor day on September 17, 2026.

15-07-2026

Yorkville Acquisition Corp. (MCGAU) entered into an amended and restated promissory note with its sponsor, Yorkville Acquisition Sponsor, LLC, increasing the principal amount to $500,000 from the original $250,000. The note is non-interest bearing, matures upon the earlier of the consummation of an initial business combination or the winding up of the company, and is convertible into units of the post-combination entity at $10.00 per unit. The sponsor has waived any claim against the trust account established in connection with the IPO, with repayment to come from trust proceeds only upon a successful business combination.

• · The note is non-interest bearing.
• · Conversion price is $10.00 per New Unit, with each New Unit having the same terms as private placement units from the IPO.
• · The sponsor waives any claim against the trust account established for the IPO, with repayment only from trust proceeds released upon a successful business combination.
• · The note amends and restates a prior note dated February 11, 2026, with an additional $250,000 advance on May 4, 2026.

15-07-2026

Lamb Weston Holdings amended its 2026 Inducement Stock Plan to reduce the authorized shares from 2,000,000 to 1,538,000 on July 13, 2026, as approved by the Compensation Committee. The plan is used to grant equity to new hires as inducements for employment under NYSE rules.

• · The reduction of authorized shares from 2,000,000 to 1,538,000 represents a decrease of 462,000 shares (23.1%).
• · The plan is intended for individuals not previously employed by the company or returning after a bona fide non-employment period.
• · The amendment was made on July 13, 2026, and the filing was dated July 15, 2026.

15-07-2026

Glucotrack, Inc. (GCTK) completed a strategic business combination with Lōkahi Therapeutics, establishing a publicly listed platform where Lōkahi becomes the controlling entity. Lōkahi securityholders are expected to hold approximately 90% of the combined company on a fully diluted basis. The deal is supported by a planned private placement, with a portion of proceeds allocated to continue Glucotrack's legacy continuous blood glucose monitoring (CBGM) technology as a separate subsidiary.

• · The transaction is structured as a reverse merger where Lōkahi Therapeutics becomes the operating and controlling business.
• · Lōkahi securityholders received a combination of Glucotrack common stock and convertible preferred stock.
• · The preferred stock conversion is subject to stockholder approvals and Nasdaq listing requirements.
• · Glucotrack's CBGM business will operate as a wholly owned subsidiary with separate operations, assets, and capital structure.
• · The combined company aims to execute a capital-efficient, repeatable strategy for acquiring and advancing healthcare assets.

15-07-2026

SBA Communications Corp. entered into an underwriting agreement on July 14, 2026 to issue $3.5 billion aggregate principal amount of senior notes in three tranches: 4.875% Senior Notes due 2030 ($1.35B), 5.150% Senior Notes due 2031 ($1.35B), and 5.450% Senior Notes due 2033 ($800M). Net proceeds will be used to repay its senior secured term loan due 2031 and outstanding borrowings under its revolving credit facility due 2029. The offering is a registered public transaction with no financial performance metrics disclosed.

15-07-2026

GameSquare Holdings granted 50,000 fully vested RSUs to its COO Amaree Vichairattanawong as a discretionary bonus on July 10, 2026. Separately, the company corrected previously invalid option grants to CEO Justin Kenna (1,045,712 shares) and CFO Michael Munoz (301,249 shares) by issuing new valid options on the same date, with 62.5% vesting immediately and the remainder vesting in one year. The filing highlights a governance correction regarding prior option grants that were not validly issued.

• · The RSUs were granted as a discretionary bonus separate from the COO's employment agreement.
• · The previously reported option awards to Kenna and Munoz (filed July 15, 2025 and amended November 14, 2025) were not validly issued; the new grants correct this.
• · Option vesting: 62.5% vests on July 10, 2026; 37.5% vests on July 10, 2027.

15-07-2026

High Wire Networks, Inc. (HWNI) disclosed on July 9, 2026 that its previously issued financial statements for three quarterly periods in 2025 should no longer be relied upon due to material errors in accounting for loan defaults. The errors resulted in an understatement of current loans payable and a failure to record a $1,376,890 non-operating loss on debt settlement, increasing total other expense and net loss. The company also identified a material weakness in internal control over financial reporting related to debt monitoring and compliance.

• · The affected filings are the 10-Q for Q1 ended March 31, 2025 (filed May 13, 2025), Q2 ended June 30, 2025 (filed Oct 14, 2025), and Q3 ended Sep 30, 2025 (filed Nov 14, 2025).
• · The company intends to file amended 10-Q/As for each affected period as soon as practicable.
• · Management concluded that disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting relating to monitoring of debt obligations and compliance with financing agreements.
• · The company has begun implementing remediation measures.

15-07-2026

Genasys Inc. amended its Term Loan Agreement to extend the maturity to July 2027 and introduce monthly amortization payments of $1.0M beginning October 2026, replacing a prior balloon-payment structure. The principal of $15.2M carries an interest rate of SOFR plus 5% and a 20% minimum guaranteed return (MOIC). Management cites strong backlog and customer demand, but the accelerated repayment schedule and elevated MOIC indicate increased debt-servicing costs and near-term liquidity obligations.

• · The maturity date was extended to July 13, 2027.
• · Interest rate remains at three-month SOFR plus 5% (no spread disclosed).
• · Monthly amortization payments of $1.0 million begin October 1, 2026, and each payment includes the 20% MOIC on the principal portion repaid.
• · The amendment replaces the prior structure of quarterly interest-only payments with a single balloon payment at maturity.
• · The company states it is 'confident in its ability to satisfy the full obligations of the Term Loan Agreement over the next 12 months.'

15-07-2026

Quality Industrial Corp. (QIND) filed an 8-K on July 15, 2026, regarding a material definitive agreement (Exhibit 10.1) that triggered Items 1.01 (entry into a material agreement), 2.03 (creation of a direct financial obligation), and 3.02 (unregistered sales of securities). The filing provides no quantitative details about the agreement, obligations, or securities issued, nor any period-over-period comparisons, making it impossible to assess financial impact or performance trends.

• · Filed under Items 1.01 (material definitive agreement), 2.03 (direct financial obligation), and 3.02 (unregistered sales of securities)
• · No agreement value, obligation amount, or security terms disclosed in the 8-K or exhibit listing

15-07-2026

Nuvalent, Inc. filed an 8-K on July 15, 2026, reporting the completion of an acquisition/disposition, as indicated by Items 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, and 9.01. The filing includes a Fourth Amended and Restated Certificate of Incorporation, which authorizes 1,000 shares of common stock at $0.0001 par value and limits director and officer liability to the fullest extent permitted by Delaware law. No financial terms or specific transaction details were disclosed in the provided exhibit.

• · The filing includes a Fourth Amended and Restated Certificate of Incorporation, indicating a corporate restructuring post-acquisition.
• · The certificate limits director and officer liability under the DGCL, except for breaches of loyalty, bad faith, intentional misconduct, or improper personal benefit.
• · No financial details (e.g., purchase price, revenue, or debt) were provided in the exhibit.

15-07-2026

First Mid Bancshares, Inc. (FMBH) entered into a $19.7 million promissory note with Bankers' Bank on July 10, 2026, bearing an initial interest rate of 6.125% per annum. The note matures on September 28, 2029, with monthly payments of $161,204.52 and a final balloon payment of approximately $17.3 million. The note is secured by a negative pledge on 100% of the outstanding shares of First Mid Bank & Trust, National Association, and includes a default interest rate of 12.000%.

• · The note renews a prior note dated September 28, 2022, and does not satisfy or discharge it.
• · Lender has an unconditional right to cancel the undrawn portion of the note at any time without notice.
• · The note is governed by federal law and, to the extent not preempted, the laws of Wisconsin; venue is Dane County, Wisconsin.
• · Borrower and lender waived the right to a jury trial.
• · Lender has a right of setoff against all of Borrower's accounts with Lender (excluding IRA, Keogh, or trust accounts where prohibited).
• · Collateral is described as 100% of the outstanding shares of First Mid Bank & Trust, National Association, secured by a Negative Pledge and Negative Assignment Agreement.

15-07-2026

NewLake Capital Partners announced that David Weinstein will resign from its Board of Directors, effective July 31, 2026. Weinstein, who served as CEO during the company's transition to public markets, has been a board member since the company's founding in 2019. The company expressed gratitude for his contributions and wished him well in future endeavors.

• · David Weinstein was a board member since NewLake's founding in 2019.
• · Weinstein served as CEO during the company's transition to public markets.
• · The resignation is effective July 31, 2026.
• · NewLake owns 34 properties: 15 cultivation facilities and 19 dispensaries, primarily under triple-net leases.

15-07-2026

Lipella Pharmaceuticals Inc. filed for Chapter 11 bankruptcy on March 30, 2026, and subsequently entered into an Asset Purchase Agreement with XRAIY on May 14, 2026, to sell substantially all of its assets. The sale was approved by the Bankruptcy Court on June 4, 2026. The company cautions that trading in its common stock during the Chapter 11 case is highly speculative and may bear little or no relationship to actual recovery for stockholders.

• · Chapter 11 petition filed on March 30, 2026, in the United States Bankruptcy Court for the Western District of Pennsylvania (Case No. 26-20879-CMB).
• · Asset Purchase Agreement entered into on May 14, 2026.
• · Sale approved by Bankruptcy Court order dated June 4, 2026 (Doc. No. 115).
• · The company is an emerging growth company.

15-07-2026

NextTrip, Inc. (NTRP) amended its Line of Credit Agreement with Monaco Investment Partners II, LP, extending the maturity date from May 31, 2027 to May 31, 2028. The amendment also confirms the agreement is non-cancelable through the new maturity date, though the borrower retains prepayment rights. No changes to the principal amount, interest rate, or other terms were disclosed.

• · Original credit agreement dated May 6, 2025 had a maturity date of May 31, 2027.
• · Amendment extends maturity by one year to May 31, 2028.
• · Agreement is non-cancelable through the new maturity date, but borrower retains prepayment rights under Section 3.2.
• · No changes to principal, interest, or other terms were mentioned.

15-07-2026

Jones Soda Co. announced the resignation of director Mark Murray, effective July 13, 2026, which was not due to any disagreement with the company. The board thanked Murray for his service and will evaluate the timing and need for appointing an additional director as part of its governance and succession-planning process.

• · Mark Murray's resignation was effective July 13, 2026.
• · The resignation was not the result of any disagreement with the company regarding operations, policies, accounting principles, financial statement disclosure, or internal controls.
• · The board will evaluate the timing and need for appointing an additional director as part of ongoing corporate governance and succession-planning.

15-07-2026

Martin Marietta Materials, Inc. entered into Amendment No. 1 to its existing $800 million Credit Agreement dated December 21, 2021, effective July 10, 2026. The amendment modifies certain provisions of the credit facility with the consent of required lenders, including JPMorgan Chase, Deutsche Bank, PNC Bank, Truist Bank, Wells Fargo, Fifth Third Bank, First-Citizens Bank, First Horizon Bank, Regions Bank, and The Northern Trust Company. The company represented that no default or event of default exists as of the amendment date.

• · The amendment was executed on July 10, 2026, and filed on July 15, 2026.
• · The Credit Agreement was originally dated December 21, 2021, and had been amended four times prior (Loan Modifications No. 1-4).
• · The amendment was approved by lenders constituting the Required Lenders.
• · The company certified that no Default or Event of Default has occurred and is continuing as of the amendment date.
• · The amendment is governed by the laws of the State of New York.

15-07-2026

Celldex Therapeutics disclosed on July 15, 2026 that CFO Sam Martin plans to retire by March 31, 2027, triggering a search for a successor. The announcement provides a long transition period but introduces key-person risk at the finance leadership level.

• · Retirement effective on or about March 31, 2027, providing a ~8.5-month transition period.
• · Sam Martin joined Celldex in April 2009 and has served as CFO since July 2017.
• · The company has initiated a search for a new CFO.
• · Mr. Martin will continue as CFO until his successor begins or March 31, 2027, whichever is earlier.
• · No financial impact or costs associated with the departure were disclosed.
• · Filing includes no financial statements beyond the cover page (Exhibit 104).